Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). (Q47782850)
Jump to navigation
Jump to search
scientific article published on 15 September 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). |
scientific article published on 15 September 2017 |
Statements
1 reference
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). (English)
1 reference
1 reference
Sibylle Loibl
1 reference
Michael Untch
1 reference
Lorena de la Pena
1 reference
Valentina Nekljudova
1 reference
Dimitrios Zardavas
1 reference
Carsten Denkert
1 reference
Mahdi Rezai
1 reference
Begoña Bermejo
1 reference
Soo Chin Lee
1 reference
Sabine Turri
1 reference
Patrick Urban
1 reference
Sherko Kümmel
1 reference
Guenther Steger
1 reference
Andrea Gombos
1 reference
Martine J Piccart
1 reference
Gunter Von Minckwitz
1 reference
José Baselga
1 reference
15 September 2017
1 reference
85
1 reference
133-145
1 reference
1 reference
1 reference
1 reference
1 reference